Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).
about
Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndromeVeno-venous extracorporeal membrane oxygenation with a heparin-coated system in adult respiratory distress syndrome.Epoprostenol in primary pulmonary hypertension.Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertensionLiposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteriesFactors that influence the outcome of primary pulmonary hypertension.New treatments for pulmonary arterial hypertension.Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery.Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.Prostacyclin in the intensive care setting.Prostanoid therapies in the management of pulmonary arterial hypertension.Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension.Lung transplantation for pulmonary hypertension.Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertensionProgress in the understanding and management of pulmonary arterial hypertension.Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and dilutedSurvival and prognostic factors in patients with primary pulmonary hypertensionEisenmenger syndrome: medical prevention and management strategies.Expert opinion on available options treating pulmonary arterial hypertension.A novel channelopathy in pulmonary arterial hypertension.Therapeutic advances in pulmonary arterial hypertension.Pulmonary hypertension-"state of the art" management in 2012.Genomics of pulmonary arterial hypertension: implications for therapy.Pharmacokinetic evaluation of continuous intravenous epoprostenol.The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.Clinical and molecular genetic features of hereditary pulmonary arterial hypertension.Pharmacotherapy of chronic pulmonary arterial hypertension: value and limitations. Part I: Primary pulmonary hypertension.The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.Treatment of primary pulmonary hypertension with continuous intravenous prostacyclinVasodilators in pulmonary hypertension.Epidural Anesthesia for Cesarean Delivery in a Patient With Severe Pulmonary Artery Hypertension and a Right-to-Left Shunt.Thromboembolism in primary pulmonary hypertension.Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension.Prostacyclin analogs as the brakes for pulmonary artery smooth muscle cell proliferation: is it sufficient to treat severe pulmonary hypertension?Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension.Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats.
P2860
Q28361771-87557A50-2815-4478-9E85-1EB4BE13DC78Q28361795-E2826F68-1365-4234-92EA-7B4A262E51D7Q33376543-619BFF64-FDAB-4FA6-841F-2CE7E08771A4Q33592445-0E987848-90C8-493F-85BA-697380C771AEQ33613468-A7493F50-0685-4D7D-9685-6B020775D389Q33890202-D291B73C-1314-42E4-A9B1-23EB8647B9E9Q33999123-10ADE226-69B1-4EE4-8597-8B7C0B71CDB4Q34625826-91AA4B3E-850E-4D41-9BA3-82E0F1026265Q34792425-17CB8CC9-604E-4400-85F1-CCDEA542B91EQ34985436-B95D971E-495A-4E23-971F-F8E0A675D8DFQ35050464-29B0C62F-B8AE-4473-A8DB-B075B5593011Q35284318-0A277B9F-1196-4749-946F-D19A783EDF61Q35368755-B4055327-4237-43C0-992A-798667854CACQ35375640-3F289366-B30D-4C17-946B-0074BF53ACD2Q35412426-9F380686-BE42-4AA9-9A2A-E2B0CE06D842Q35579856-31DFEFC6-54F4-495D-BA25-A63D51453767Q35662646-D9DBC697-C315-4DD4-80C2-3855C9B90EE8Q35922093-EF26576E-CF5A-488C-9A9B-D20FDCC3373EQ35937528-8E54996A-7415-4DC9-995E-33717D7991DEQ36273440-D8A10FD4-1F44-4038-B7EF-33FF8801293FQ36967262-A289235A-A313-4132-ACB8-6AEEDFFBA2FBQ37219463-D64630B5-EB1F-4AA6-B820-D5FF88F0F10AQ37362631-1BB7ED2E-A59A-448E-8FDF-E393E8AE47C2Q37387305-E9C2AB33-B70D-4295-BE44-D69F2FB7B1D2Q37452405-9E2571E7-A3C9-41D7-B9AD-AFB61F0C7562Q37809538-A24E6539-0424-4F0C-9836-C61E1D9A917DQ37837276-797219BE-B3D4-4C9A-B807-D704ED3E0BD4Q37879213-367B276F-45C3-4AD5-8B5F-9B798AB79CE7Q38111740-EE3C5F1B-67D9-498A-BA02-4B2057CA0A1AQ40624806-DB2023B0-2E82-40CA-A0B2-17542CF8A58DQ40926240-94FF9600-F066-4353-AD62-1943EE5AB166Q42390536-BDAD3AC4-EDA0-4515-9A4A-861560562428Q42504171-BA29DE0E-9EEE-4DC2-9AA3-C2221B123C55Q42735064-FD377233-3147-425C-8694-6D1FD4390BC6Q43191112-54078DB0-9FEC-42E5-A929-2039A43E35D5Q43562548-49FD97EA-230F-467F-B458-BD6CC43C1D53Q43862670-3580203A-DF02-4B84-BFA2-FC53748CD43BQ43862678-BFD56747-A497-4B93-951A-5B026828CEFBQ43871209-2D31E1D8-B195-4A2E-87DA-9F696628EF3AQ44619356-6F87B92A-C7EE-4FA4-8573-0BD45DF7F753
P2860
Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin).
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Long-term treatment of primary ...... s epoprostenol (prostacyclin).
@en
Long-term treatment of primary ...... nuous intravenous epoprostenol
@nl
type
label
Long-term treatment of primary ...... s epoprostenol (prostacyclin).
@en
Long-term treatment of primary ...... nuous intravenous epoprostenol
@nl
prefLabel
Long-term treatment of primary ...... s epoprostenol (prostacyclin).
@en
Long-term treatment of primary ...... nuous intravenous epoprostenol
@nl
P2093
P1433
P1476
Long-term treatment of primary ...... s epoprostenol (prostacyclin).
@en
P2093
D Wheeldon
J Wallwork
T Higenbottam
P304
P356
10.1016/S0140-6736(84)91452-1
P407
P577
1984-05-01T00:00:00Z